Pathway Financial Advisers’s Pfizer PFE Stock Holding History

Pathway Financial Advisers’s Portfolio PFE Stock Details PFE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$1.39M	Buy	57,903 +3,924	+7%	+$103K	0.35%	92
2026 Q1	$1.52M	Buy	53,979 +7,599	+16%	+$202K	0.43%	81
2025 Q4	$1.15M	Buy	46,380 +403	+0.9%	+$10.2K	0.33%	93
2025 Q3	$1.17M	Buy	45,977 +4,365	+10%	+$108K	0.34%	92
2025 Q2	$1.01M	Buy	41,612 +1,733	+4%	+$40.4K	0.33%	95
2025 Q1	$1.01M	Buy	39,879 +1,034	+3%	+$27.1K	0.35%	89
2024 Q4	$1.03M	Sell	38,845 -760	-2%	-$20.6K	0.35%	90
2024 Q3	$1.15M	Sell	39,605 -17,982	-31%	-$525K	0.52%	60
2024 Q2	$1.61M	Sell	57,587 -1,091	-2%	-$30K	0.58%	63
2024 Q1	$1.63M	Buy	58,678 +6,823	+13%	+$189K	0.59%	61
2023 Q4	$1.49M	Sell	51,855 -3,302	-6%	-$99.8K	0.57%	61
2023 Q3	$1.83M	Buy	+55,157	New	+$1.95M	0.76%	46
2023 Q1	$2.24M	Sell	54,798 -2,354	-4%	-$102K	0.9%	35
2022 Q4	$2.93M	Buy	+57,152	New	+$2.74M	1.19%	24

Other funds holding PFE

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Fisher Asset Management Camas, Washington $336B AUM 34.66% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Norges Bank Oslo, Norway $1T AUM

Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return

Pathway Financial Advisers's PFE Position: Q2 2026 in Review

Pathway Financial Advisers increased its Pfizer (PFE) stake by 7.3% in Q2 2026, buying an estimated $103K and bringing the position to 57,903 shares worth $1.39M. The position accounts for 0.35% of the portfolio, ranked #92.

Pathway Financial Advisers first reported a position in PFE in Q4 2022 and has held it in 14 quarters since. The position peaked at $2.93M in Q4 2022. 2,823 funds tracked by Wall St. Rank hold PFE as of Q2 2026.

Pathway Financial Advisers held 57,903 shares of Pfizer worth $1.39M as of Q2 2026.
Pathway Financial Advisers bought 3,924 Pfizer shares in Q2 2026, an estimated $103K.
Pfizer made up 0.35% of Pathway Financial Advisers's portfolio in Q2 2026, its #92 holding.
Pathway Financial Advisers first reported a position in Pfizer in Q4 2022 and has held it in 14 quarters since.
Pathway Financial Advisers's Pfizer position peaked at $2.93M in Q4 2022.
2,823 funds tracked by Wall St. Rank held Pfizer as of Q2 2026.

Based on Pathway Financial Advisers's 13F filing for Q2 2026, filed 30 Jul 2026.